Recent studies have revealed that SLC7A11 is overexpressed in various cancer types, and promotes cancer progression by inhibiting ferroptosis [37], e.g., lung cancer [38], breast cancer [39], bladder cancer [40], et al., demonstrating it as a potential therapeutic target. This evidence concerns the gene SLC7A11 and breast carcinoma.